To investigate the outcome of single amniotic membrane transplantation (AMT) in treating corneal melting associated with ocular graft-versus-host disease (oGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) and explore correlative risk factors, highlighting the significance of this treatment in improving patient outcomes.
Key Findings:
31 patients were enrolled; 21 males (67.74%).
At 6 months post-AMT, 21 cases achieved corneal healing, while 10 cases experienced recurrence.
Higher incidence of lung GVHD in the failure group (OR = 8.021, p = 0.020).
Interpretation:
AMT is a viable treatment for oGVHD-related corneal melting, with lung GVHD potentially influencing surgical failure, suggesting implications for clinical practice.
Limitations:
Retrospective design may introduce bias, including selection bias.
Small sample size limits generalizability and the ability to draw broader conclusions.
Conclusion:
AMT can be effective for treating corneal melting due to oGVHD, and attention to lung GVHD may improve outcomes, warranting further investigation in future studies.
